MiR-210 in lung cancer cell-derived EVs is transferred to fibroblasts, where it inhibits TET expression, leading to CAF differentiation, activation of JAK/STAT signaling, and expression of pro-angiogenic VEGF, MMP9, and FGF2. This evidence concerns the gene MMP9 and lung carcinoma.